Hybrid molecules based on 1, 3, 5‐triazine as potential therapeutics: A focused review. Issue 7 (24th June 2020)

• Record Type: Journal Article
• Authors: Prasher, Parteek; Sharma, Mousmee; Aljabali, Alaa A. A.; Gupta, Gaurav; Negi, Poonam; Kapoor, Deepak N.; Singh, Inderbir; Zacconi, Flavia C.; de Jesus Andreoli Pinto, Terezinha; da Silva, Mateus Webba; Bakshi, Hamid A.; Chellappan, Dinesh Kumar; Tambuwala, Murtaza M.; Dua, Kamal
• Is Part Of: Drug development research. Volume 81:Issue 7(2020)
• Page Start: 837
• Page End: 858
• Publication Date: 2020-06-24
• Subjects: 1, 3, 5‐triazine -- anti‐Alzheimer's activity -- anticancer activity -- anti‐inflammatory activity -- antimicrobial activity -- antiplasmodial activity -- hybrids -- multidrug‐resistance; Drug development -- Periodicals; Drugs -- Research -- Periodicals; 615.19
• DOI: 10.1002/ddr.21704
• Languages: English
• ISSNs: 0272-4391

Abstract

Abstract: Majority of the representative drugs customarily interact with multiple targets manifesting unintended side effects. In addition, drug resistance and over expression of the cellular efflux‐pumps render certain classes of drugs ineffective. With only a few innovative formulations in development, it is necessary to identify pharmacophores and novel strategies for creating new drugs. The conjugation of dissimilar pharmacophoric moieties to design hybrid molecules with an attractive therapeutic profile is an emerging paradigm in the contemporary drug development regime. The recent decade witnessed the remarkable biological potential of 1, 3, 5‐triazine framework in the development of various chemotherapeutics. The appending of the 1, 3, 5‐triazine nucleus to biologically relevant moieties has delivered exciting results. The present review focuses on 1, 3, 5‐triazine based hybrid molecules in the development of pharmaceuticals.